ReviewDrug design, development and therapy2026
Progress in the Treatment of Ulcerative Colitis by Targeting NLRP3 Inflammasome.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory disease occurred in intestinal tract, characterized by a prolonged treatment course and associated with severe complications, exerting significant negative impacts on patients' quality of life. In recent years, the incidence of UC has been increasing. Consequently, identifying novel therapeutic targets and innovative drugs is of paramount importance for UC treatment. The aberrant activation of NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammasome exacerbates intestinal mucosal damage through releasing inflammatory cytokines. Thus, targeting NLRP3 inflammasome to inhibit its activation has emerged as a breakthrough strategy for UC therapy. Small molecule compounds can apply inhibitory effects by binding to NLRP3-associated domains and modulating the activation phase. In this review, we describe the mechanism of NLRP3 inflammasome and systematically summarizes compounds targeting different domains of NLRP3 inflammasome, along with their core structures. Furthermore, candidate compounds and those validated in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.